Document Detail

Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers.
MedLine Citation:
PMID:  23292239     Owner:  NLM     Status:  Publisher    
The optimal protocol for mobilization of hematopoietic stem cells in patients with lymphoid malignancies has not been determined so far. We retrospectively analyzed the efficacy and safety of Ara-C at a dose of 1.6 g/m(2) compared with CY at a dose of 4.0 g/m(2), both combined with filgrastim. Seventy and forty-five patients, respectively, were included, among whom 60% were defined as 'predicted poor mobilizers'. The use of Ara-C was associated with significantly higher peak number of circulating CD34(+) cells compared with CY (P<0.0001). In the Ara-C group, 95% of patients with multiple myeloma (MM) collected at least 5 × 10(6) CD34(+) cells/kg required for tandem transplantation, and 97% of lymphoma patients collected at least 2 × 10(6) CD34(+) cells/kg, needed for a single autologous hematopoietic SCT (autoHSCT), which was achieved with a single leukapheresis in 91% of cases. Results for the CY group were significantly inferior (P<0.0001). No patient mobilized with Ara-C experienced febrile neutropenia, whereas 35% required platelet transfusions. Among patients who proceeded to autoHSCT, the time of both neutrophil and platelet recovery was significantly shorter for those mobilized with Ara-C than CY. We conclude that intermediate-dose Ara-C+filgrastim is a very effective and relatively safe mobilization protocol for patients with lymphoid malignancies.Bone Marrow Transplantation advance online publication, 7 January 2013; doi:10.1038/bmt.2012.269.
S Giebel; T Kruzel; T Czerw; M Sadus-Wojciechowska; J Najda; E Chmielowska; S Grosicki; A Jurczyszyn; M Pasiarski; E Nowara; M Glowala-Kosinka; A Chwieduk; I Mitrus; A Smagur; J Holowiecki
Related Documents :
24575499 - Changes in anti-citrullinated protein antibody titers following treatment with inflixim...
23741089 - Annual change in spirometric parameters among patients affected in bhopal gas disaster:...
23215569 - Myd88 l265p somatic mutation in igm mgus.
24582759 - Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitti...
23828069 - Loss of consciousness and convulsion induced by a ventricular tachycardia mimicking epi...
16401649 - Formation of immature neutrophil leucocytes in schizophrenic patients treated with vari...
765189 - Pasteurella multocida peritonitis in hepatic cirrhosis with ascites.
24500829 - Histology of failed metal-on-metal hip arthroplasty; three distinct sub-types.
10063739 - Early changes in esophageal motility after endoscopic variceal sclerotherapy or ligation.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-07
Journal Detail:
Title:  Bone marrow transplantation     Volume:  -     ISSN:  1476-5365     ISO Abbreviation:  Bone Marrow Transplant.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-7     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8702459     Medline TA:  Bone Marrow Transplant     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Bone Marrow Transplantation, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Surviving the cure: long term followup of hematopoietic cell transplant recipients.
Next Document:  Management of acquired aplastic anemia in children.